1 min read
Add as a preferred source on GoogleVaxcyte Posts $1.99 Q3 GAAP Loss Per Share, 15 Cents Better Than Estimate
Cash, cash equivalents and investments totaled $2,264.4 million on Sept. 30, down from $2,442.6 million at year-end 2025.
In results announced Nov. 4, Vaxcyte posted a third-quarter GAAP loss of $1.99 per share, 15 cents better than the estimate, while cash, cash equivalents and investments totaled $2,264.4 million at Sept. 30.
The combined balance was $2,442.6 million at Dec. 31, 2025.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.